Contrave Tablet, Extended Release
Product Images NDC 51267-890

6 FDA label images from Nalpropion Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Contrave (NDC 51267-890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nalpropion Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Contrave 01)

Chemical Structure (Contrave 01)
Chemical structure of naltrexone hydrochloride, part of the active ingredients in Contrave Extended-Release tablets.*
FDA Label Image

Chemical Structure (Contrave 02)

Chemical Structure (Contrave 02)
Chemical structure of naltrexone hydrochloride, one of the active ingredients in Contrave Extended-Release tablets.*
FDA Label Image

Figure 1 (Contrave 03)

Figure 1 (Contrave 03)
A line graph depicting weight change from baseline (%) over 56 weeks. It compares weight loss between patients taking placebo and those taking Contrave Extended-Release (labelled as CONTRA VE 32/360). The graph shows two lines: placebo indicated by open circles and Contrave by filled triangles. Weight decreases more substantially with Contrave compared to placebo throughout the study period.*
FDA Label Image

Figure 2 (Contrave 04)

Figure 2 (Contrave 04)
A line graph showing weight change from baseline (%) over a period of 56 weeks. Two data series are displayed: one for Placebo (open circles) and one for CONTRAVE ER 32/360 (filled triangles). The graph illustrates weight change trends for completers and ITT-LOCF populations, with the CONTRAVE group showing a greater reduction in weight compared to the placebo group.*
FDA Label Image

Figure 3 (Contrave 05)

Figure 3 (Contrave 05)
A line graph depicting weight change from baseline (%) over 56 weeks comparing placebo and Contrave Extended-Release 32/360 mg. The x-axis shows weeks, and the y-axis shows percentage weight change. The graph indicates a greater weight reduction with Contrave compared to placebo throughout the study period.*
FDA Label Image

Principal Display Panel (8 mg/90 mg Tablet Bottle Label)

Principal Display Panel (8 mg/90 mg Tablet Bottle Label)
Label for Contrave Extended-Release Tablets containing 8 mg naltrexone HCl and 90 mg bupropion HCl. The label shows a bottle containing 120 tablets, manufactured by Nalpropion Pharmaceuticals LLC and distributed by Currax Pharmaceuticals LLC. It includes storage instructions, a barcode, and a warning to dispense with the medication guide. The label indicates the tablets should not be cut, chewed, or crushed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.